The Clatterbridge Cancer Centre
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 5 July 2021

Re: Freedom of Information Request
Ref: 163-2021

Thank you for your email dated the 7th June 2021, requesting information in relation to patient treatment figures and trials.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000.The areas where this exemption has been applied are shown below:

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- **Atezolizumab = 25**
- **Carboplatin with Gemcitabine = 17**
- **Carboplatin single or in any other combination**
    - **Carboplatin = Exempt under S.40**
    - **Carboplatin + Etoposide = Exempt under S.40**
- **Cisplatin with Gemcitabine = 31**
- **Cisplatin single or in any other combination = 0**
- **Nivolumab = 38**
- **Pembrolizumab = Exempt under S.40**
- **Any other regimen including Paclitaxel**
    - **Paclitaxel = Exempt under S.40**
- **Any other chemotherapy regimen**

    - **Gemcitabine = Exempt under S.40**
    - **Everolimus = 11**
    - **Doxorubin = Exempt under S.40**
- **Other active systemic anti-cancer therapy [please state]**
    - **Tivozanib = 24**
    - **Sunitinib = Exempt under S.40**
    - **Pazopanib = Exempt under S.40**
    - **Cabozantinib = 44**
    - **Axitinib + Avelumab = 33**
    - **Lenvatinib = 10**
    - **Ipilimumab = 7**
    - **Duralumab = Exempt under S.40**
    - **Ramucirumab = Exempt under S.40**
    - **Fluorouracil + Mitomycin + Radiotherapy = Exempt under S.40**
    - **Megestrol Acetate = Exempt under S.40**
- **Palliative care only* = 12**

Had a palliative care appointment with CCC Palliative Care Team (unable to report on patients interacting with Community Palliative Care Teams) and were not receiving SACT or Radiotherapy.

Q2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Urothelial – Open to Recruitment

Project Short Title	Project Full title	Project type	Recruited
ATLANTIS BLADDER	An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer	Non-commercial portfolio	0
ANNAR (EDDA)	Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations	Commercial portfolio	Exempt under S.40

Urothelial – Follow-up

Project Short Title	Project Full title	Project type	Recruited
MK3475	A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	Commercial portfolio	Exempt under S.40

RANGE	RANGE - Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Commercial portfolio	12
JANSSEN BLADDER	A Phase II, 2-Arm Multicentre, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	Commercial portfolio	Exempt under S.40
BAYER 17403	A randomized, open label, multicentre Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	Commercial portfolio	10
EV-301	An Open-Label, Randomised Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	Commercial portfolio	Exempt under S.40
POUT	POUT - A Phase III randomised trial of Perioperative chemotherapy versus surveillance in upper Tract urothelial cancer	Non-commercial portfolio	6

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- **Afatinib** = 21
- **Alectinib** = 11
- **Atezolizumab monotherapy** = 30
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel** = 10
- **Bevacizumab** = Exempt under S.40
- **Brigatinib** = 6
- **Ceritinib** = Exempt under S.40
- **Crizotinib** = Exempt under S.40
- **Dacomitinib** = Exempt under S.40

- **Dabrafenib with Trametinib = 0**
- **Docetaxel = Exempt under S.40**
- **Durvalumab = 16**
- **Erlotinib = 11**
- **Gefitinib = Exempt under S.40**
- **Gemcitabine = Exempt under S.40**
- **Nintedanib with Docetaxel = 6**
- **Nivolumab = Exempt under S.40**
- **Osimertinib = 50**
- **Paclitaxel = 0**
- **Pembrolizumab monotherapy = 111**
- **Pembrolizumab chemo in combination**
    - **Carboplatin + Pemetrexed + Pembrolizumab = 51**
    - **Cisplatin + Pemetrexed + Pembrolizumab = Exempt under S.40**
- **Pemetrexed with Carboplatin = 23**
- **Pemetrexed with Cisplatin = 0**
- **Vinorelbine and cisplatin/carboplatin = 51**
- **Any other active systemic anti-cancer therapy**
    - **Carboplatin = Exempt under S.40**
    - **Carboplatin + Etoposide = Exempt under S.40**
    - **Gemcitabine + Carboplatin = 25**
    - **Gemcitabine + Cisplatin = Exempt under S.40**
    - **Lorlatinib = 7**
    - **Pemetrexed + Pembrolizumab = 20**
    - **Octreotide = 10**
    - **Nintednanib = Exempt under S.40**
    - **Cisplatin + Radiotherapy = Exempt under S.40**
    - **Carboplatin + Paclitaxel = 16**
    - **Pemetrexed = 10**
    - **Enrectinib = Exempt under S.40**
    - **Capecitabine + Irinotecan = Exempt under S.40**
    - **Atezolizumab + Bevacizumab = Exempt under S.40**
    - **Lenvatinib = Exempt under S.40**
    - **Everolimus = Exempt under S.40**
    - **Cisplatin + Etoposide = Exempt under S.40**
    - **Canakinumab = Exempt under S.40**
- **Palliative care only* = *9***

Had a palliative care appointment with CCC Palliative Care Team (unable to report on patients interacting with Community Palliative Care Teams) and were not receiving SACT or Radiotherapy.

Q4. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Non-Small Cell Lung Cancer – Open to Recruitment

Project Short Title	Project Full title	Project type	Recruited
National Lung Matrix	National Lung Matrix Trial: Multi--drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	Non-commercial portfolio	Exempt under S.40
SARON	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial.	Non-commercial portfolio	16
ADSCAN	A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer.	Non-commercial portfolio	Exempt under S.40
ACZ885 CANAKINUMAB (CANOPY)	A phase III, multicentre, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	Commercial portfolio	Exempt under S.40
KEYNOTE 671	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Commercial portfolio	0
IMPower	A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON−SMALL CELL LUNG CANCER	Commercial portfolio	Exempt under S.40
LEAP-006	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the	Commercial portfolio	Exempt under

	Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Non-squamous Non-small Cell Lung Cancer (LEAP-006)		S.40
KEYNOTE 867	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	Commercial portfolio	0
CA209-73L	A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Commercial portfolio	Exempt under S.40
FLAURA-2	A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)	Commercial portfolio	Exempt under S.40

Non-Small Cell Lung Cancer – Follow-up

Project Short Title	Project Full title	Project type	Recruited
CHECKMATE 171	Checkmate 171: An Open-Label, Multicentre Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen for the	Commercial portfolio	23

	Treatment of Stage IIIb/IV SqNSCLC		
LDK378 Food Affect Study	**A Phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)**	**Commercial portfolio**	**7**
ABI-007-NSCL-006	**A Phase 2, randomized, open-label, multicentre study to assess safety and efficacy of nabpaclitaxel (Abraxane) with epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced non-squamous non-small cell lung cancer (NSCLC): ABOUND.2L**	**Commercial portfolio**	**16**
JAVELIN LUNG	**A Phase III, open-label, multicentre trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non–small-cell lung cancer**	**Commercial portfolio**	**Exempt under S.40**
XALT-3	**Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients**	**Commercial portfolio**	**Exempt under S.40**
PS2	**A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.**	**Commercial portfolio**	**Exempt under S.40**
LUNG ART	**Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement**	**Non-commercial portfolio**	**Exempt under S.40**
IDEAL-CRT	**Isotoxic Dose Escalation and Acceleration in Lung Cancer**	**Non-commercial**	**10**

	ChemoRadiotherapy - A phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer	**portfolio**	

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM